CTLA-4 inhibitors, such as ipilimumab, have demonstrated favorable efficacy in the treatment of melanoma, colorectal cancer (CRC), and hepatocellular carcinoma (HCC) (40). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.